Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673250 | 0.86 | SIGMAR1 (0.56) | LMNAGAAKDM4ESIGMAR1IGF1R | |
| SCHEMBL24672258 | 0.83 | KDM4E (0.51) | LMNAGAAKDM4ESIGMAR1IGF1R | |
| SCHEMBL24673260 | 0.79 | APOBEC3A (0.51) | LMNAGAAKDM4ESIGMAR1 | |
| SCHEMBL12781846 | 0.77 | KDM4E (0.66) | LMNAGAAKDM4ESIGMAR1IGF1R | |
| SCHEMBL29201748 | 0.77 | KDM4E (0.66) | LMNAGAAKDM4ESIGMAR1IGF1R | |
| SCHEMBL24673253 | 0.74 | MPO (0.48) | LMNAGAAKDM4E | |
| SCHEMBL24673327 | 0.73 | POLB (0.53) | LMNAKDM4E | |
| SCHEMBL24673197 | 0.73 | KDM4E (0.45) | KDM4E | |
| SCHEMBL9621424 | 0.73 | SLC6A4 (0.68) | SLC6A4SLC6A3 | |
| SCHEMBL24672858 | 0.73 | HDAC4 (0.46) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204065-A1 | IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-29 | — | — | WO | disclosed |